Inhibitor binding to topoisomerase II leading to infant leukaemia

Olavi Pelkonen, Andrea Terron, Antonio F. Hernandez, Pablo Menendez and Susanne Hougaard Bennekou

No 21, OECD Series on Adverse Outcome Pathways from OECD Publishing

Abstract: This Adverse Outcome Pathway (AOP) describes the linkages between the perturbation of the normal topoisomerase II enzyme function and infant leukaemia. Infant leukaemia is a rare haematological disease (1 in 106 newborns, accounting for 10% of all childhood acute lymphoblastic leukaemias) of developmental origin, manifesting soon after birth (

Keywords: Genotoxicity; Infant leukaemia; Topoisomerase II (search for similar items in EconPapers)
Date: 2022-12-15
References: Add references at CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1787/4782fbfc-en (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oec:envaad:21-en

Access Statistics for this paper

More papers in OECD Series on Adverse Outcome Pathways from OECD Publishing Contact information at EDIRC.
Bibliographic data for series maintained by ().